UroGen Pharma stock (IL0011408896): CMO sells 10K shares at $30

UroGen Pharma Ltd shares drew attention after Chief Medical Officer Mark Schoenberg disclosed selling 10,000 ordinary shares at a weighted average price of about $30.00 on May 8, 2026. The transaction, executed under a Rule 10b5-1 trading plan adopted on August 15, 2025, left him with 134,985 shares, according to the SEC Form 4 filing as of May 11, 2026. Separately, the company reported strong Q1 2026 results with $51 million in revenue, up 152% year-over-year.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

UroGen Pharma: core business model

UroGen Pharma Ltd develops and commercializes novel therapies using its proprietary RTGel technology for urological cancers and diseases. The platform enables sustained release of therapeutics directly into the urinary tract, minimizing systemic exposure. Key products include Jelmyto for low-grade intermediate-risk non-muscle invasive bladder cancer and UGN-102 (zuszuduri) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, recently launched in the US market. The company, listed on Nasdaq under URGN, focuses on uro-oncology with significant exposure to the US healthcare system.

Main revenue and product drivers for UroGen Pharma

Jelmyto remains the primary revenue driver, generating the bulk of Q1 2026 sales as reported in earnings released recently, with total revenue hitting $51 million, up 152% from the prior year according to Investing.com as of May 2026. UGN-102 launch contributes to growth momentum. The stock traded at $31.33 on May 11, 2026 on Nasdaq, up 6.56% from $29.40, per StockInvest.us as of May 11, 2026. US investors track these developments given the company's Nasdaq listing and focus on American urology markets.

Industry trends and competitive position

The uro-oncology sector sees rising demand for targeted bladder cancer treatments amid an aging US population. UroGen differentiates via RTGel's site-specific delivery, competing with cystectomy standards and emerging immunotherapies. Q1 revenue beat forecasts by 14.62%, signaling strong Jelmyto adoption and Zusduri uptake.

Why UroGen Pharma matters for US investors

As a Nasdaq-listed biotech with products approved by the FDA, UroGen offers US investors direct exposure to innovative urology solutions addressing a key segment of the $10B+ US oncology market. Revenue growth ties to domestic reimbursement and physician adoption.

Conclusion

UroGen Pharma Ltd reported robust Q1 2026 revenue growth alongside a routine insider sale by its CMO under a pre-planned Rule 10b5-1 transaction. The stock's recent gains reflect positive market reception to earnings. Investors monitor upcoming catalysts like product expansions in the US uro-oncology space.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.